This week sees new and notable appointments at McCann FitzGgerald LLP, RGFI, Spark Foundry, Irish Writers Centre, and Takeda ...

Hernán’s appointment comes at a pivotal moment as Takeda intensifies its focus on advancing sustainable, value-based ...

First Devices Customized for a Plasma-Derived Therapy in Takeda’s Broad and Differentiated Portfolio Reflect Company’s Commitment to Providing a Patient-Centric Ecosystem of Support Takeda ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

The elritercept Phase 3 RENEW clinical trial (NCT06499285) is a global, randomized, double-blind, placebo-controlled trial in adults with transfusion-dependent anemia with very low, low, and ...

Japan’s largest pharma company Taked today announced that all primary and secondary endpoints were met in two Phase III ...

Investing.com -- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) stock rose 3.5% following the announcement of positive Phase 3 trial results for its investigational narcolepsy treatment oveporexton. The ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

Takeda offers strong cash flow, solid growth in key areas, and a 4.4% yield, but trades at a premium despite its fundamentals ...

Only a few years ago, the largest construction projects in Massachusetts spoke to the region’s booming economy. Now, with ...

Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyout By Nick Paul Taylor Jun 27, 2025 9:00am Turnstone Biologics Xoma mergers and acquisitions Oncology ...